Key result
Selectin inhibition reduces thrombosis and vein wall fibrosis without increasing bleeding risk in VTE.
Answers are grounded in this paper and cite their sources.
Venous thromboembolism is a very common and costly health problem worldwide. Anticoagulant treatment for VTE is imperfect: all have the potential for significant bleeding, and none prevent the development of post thrombotic syndrome after deep vein thrombosis or chronic thromboembolic pulmonary hypertension after pulmonary embolism. For these reasons, alternate forms of therapy with improved efficacy and decreased bleeding are needed. Selectins are a family (P-selectin, E-selectin, L-selectin) of glycoproteins that facilitate and augment thrombosis, modulating neutrophil, monocyte, and platelet activity. P- and E-selectin have been investigated as potential biomarkers for thrombosis. Inhibition of P-selectin and E-selectin decrease thrombosis and vein wall fibrosis, with no increase in bleeding. Selectin inhibition is a promising avenue of future study as either a stand-alone treatment for VTE or as an adjunct to standard anticoagulation therapies.
No takes yet. Share an insight, caveat, or question.
Purdy et al. (2022) conducted a review in Venous thromboembolism. Selectin inhibition (P-selectin and E-selectin) was evaluated. Inhibition of P-selectin and E-selectin decreases thrombosis and vein wall fibrosis with no increase in bleeding, presenting a promising avenue for VTE treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: